HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Ionis Pharmaceuticals (NASDAQ: IONS) and maintained a price target of $100 for the stock.